Key Takeaways
- • IMU Biosciences closed an oversubscribed Series A extension totaling US$53 million (£40m/€46m), co-led by IQ Capital and Molten Ventures with participation from the British Business Bank, Meltwind, and existing investors.
- • The London-based biotech company's immune-profiling platform generates over 100 million immune data points from a single 2ml blood sample and resolves approximately 2,500 immune cell subsets in real time, leveraging a dataset sourced from more than 25,000 individuals as of 2026.
- • Capital will fund operational scaling, clinical platform development, and advancement of three therapeutic focus areas: haematopoietic stem cell transplantation, solid organ transplantation, and immuno-oncology, with applications targeting graft efficacy prediction, rejection prevention, and checkpoint inhibitor response.
- • IMU Biosciences, founded on research from the Francis Crick Institute and King's College London, aims to establish a universal standard for immune profiling by combining multi-omic analysis with machine-learning analytics to enable precision medicine applications.
Summary
IMU Biosciences, a London-based immunology platform company, has completed an oversubscribed Series A financing round bringing total capital raised to US$53 million. The round was co-led by IQ Capital and Molten Ventures, with co-investment from the British Business Bank, Meltwind, and previous backers. The company intends to deploy proceeds toward operational expansion, clinical platform infrastructure development, and advancement of three clinical-stage programs spanning transplantation and oncology indications.
The company's core technology generates high-resolution immune profiling from minimal sample volume. IMU's platform extracts more than 100 million immune data points from a 2ml blood sample and identifies approximately 2,500 distinct immune cell subsets in real time. The company has assembled what it characterizes as the world's largest immune dataset, encompassing samples from over 25,000 individuals as of 2026. By integrating multi-omic analysis with machine-learning algorithms, IMU is working to establish standardized immune profiling as a clinical tool for predicting treatment response, monitoring disease progression, and identifying immune mechanisms to guide precision medicine development.
IMU's three near-term clinical focuses reflect areas where immune status is a critical determinant of outcomes. In haematopoietic stem cell transplantation, the company is developing predictive tools to assess graft efficacy. In solid organ transplantation, IMU is advancing tools to predict graft rejection risk. In immuno-oncology, the company is identifying immune signatures predictive of response and adverse events to checkpoint inhibitor therapies. The company was founded on intellectual property and research originating from the Francis Crick Institute and King's College London, establishing scientific credibility within high-complexity immunology domains.
The company's core technology generates high-resolution immune profiling from minimal sample volume. IMU's platform extracts more than 100 million immune data points from a 2ml blood sample and identifies approximately 2,500 distinct immune cell subsets in real time. The company has assembled what it characterizes as the world's largest immune dataset, encompassing samples from over 25,000 individuals as of 2026. By integrating multi-omic analysis with machine-learning algorithms, IMU is working to establish standardized immune profiling as a clinical tool for predicting treatment response, monitoring disease progression, and identifying immune mechanisms to guide precision medicine development.
IMU's three near-term clinical focuses reflect areas where immune status is a critical determinant of outcomes. In haematopoietic stem cell transplantation, the company is developing predictive tools to assess graft efficacy. In solid organ transplantation, IMU is advancing tools to predict graft rejection risk. In immuno-oncology, the company is identifying immune signatures predictive of response and adverse events to checkpoint inhibitor therapies. The company was founded on intellectual property and research originating from the Francis Crick Institute and King's College London, establishing scientific credibility within high-complexity immunology domains.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.